A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Sponsor
Genentech, Inc.
Study ID
NCT00382148
Phase
PHASE2
Status
Completed

Conditions

  • Peanut Hypersensitivity

Eligibility Criteria

Sex
ALL
Age
6 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Key Dates

Start date
Nov 30, 2006
Status verified
May 2026
Primary completion
Jun 28, 2008
Completion
Jun 28, 2008

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Serious Adverse Events [ Time Frame: Through Week 52 ]

Related Studies